Members |
targetComponentId |
Hydrocephalic disproportion with antenatal problem |
Hydrocephalic disproportion |
Hydrochlorothiazide + quinapril hydrochloride |
Product containing hydrochlorothiazide and quinapril (medicinal product) |
Hydrochlorothiazide + quinapril hydrochloride 12.5mg/10mg tablet |
Hydrochlorothiazide 12.5 mg and quinapril (as quinapril hydrochloride) 10 mg oral tablet |
Hydrochlorothiazide 25mg |
Hydrochlorothiazide 25 mg oral tablet |
Hydrocortisone 1% + Pramocaine 1% conventional release rectal foam |
Hydrocortisone and pramocaine only product |
Hydrocortisone 1% + Pramocaine 1% foam enema |
Hydrocortisone and pramocaine only product |
Hydrocortisone 100mg powder and solvent for injection solution vial |
Hydrocortisone (as hydrocortisone sodium succinate) 100 mg powder for solution for injection vial |
Hydrocortisone 100mg/60mL |
Product containing precisely hydrocortisone 1.67 milligram/1 milliliter conventional release rectal suspension (clinical drug) |
Hydrocortisone 100mg/60mL enema |
Product containing precisely hydrocortisone 1.67 milligram/1 milliliter conventional release rectal suspension (clinical drug) |
Hydrocortisone 2% topical lotion |
Hydrocortisone acetate 20 mg/mL cutaneous lotion |
Hydrocortisone acetate 1% eye drops |
Hydrocortisone 10 mg/mL eye solution |
Hydrocortisone acetate 2.5% cream |
Product containing precisely hydrocortisone 25 milligram/1 milliliter conventional release cutaneous cream (clinical drug) |
Hydrocortisone acetate+neomycin sulfate 1.5%/0.5% eye drops |
Hydrocortisone acetate 15 mg/mL and neomycin (as neomycin sulfate) 5 mg/mL eye solution |
Hydrocortisone cypionate 10mg/5mL suspension |
Product containing precisely hydrocortisone 2 milligram/1 milliliter conventional release oral suspension (clinical drug) |
Hydrocortisone/neomycin cream |
Hydrocortisone acetate 10 mg/g and neomycin sulfate 5 mg/g cutaneous cream |
Hydrolyase |
Hydrolyase |
Hydromorphone hydrochloride 100% powder |
Hydromorphone only product |
Hydromorphone hydrochloride 12mg m/r capsule |
Product containing only hydromorphone in oral dose form (medicinal product form) |
Hydromorphone hydrochloride 12mg prolonged-release oral capsule |
Product containing only hydromorphone in oral dose form (medicinal product form) |
Hydromorphone hydrochloride 1mg/mL injection solution ampule |
Hydromorphone hydrochloride 1 mg/mL solution for injection |
Hydromorphone hydrochloride 32mg m/r capsule |
Product containing only hydromorphone in oral dose form (medicinal product form) |
Hydromorphone hydrochloride 32mg prolonged-release oral capsule |
Product containing only hydromorphone in oral dose form (medicinal product form) |
Hydromorphone hydrochloride 4mg/mL injection solution ampule |
Hydromorphone hydrochloride 4 mg/mL solution for injection |
Hydrotherapy NOS |
Hydrotherapy |
Hydrotherapy NOS |
Hydrotherapy |
Hydrous wool fat+zinc oxide 4/8% conventional release cutaneous cream |
Lanolin and zinc oxide only product in cutaneous dose form |
Hydrous wool fat+zinc oxide 4/8% cream |
Lanolin and zinc oxide only product in cutaneous dose form |
Hydroxocobalamin 1mg/mL injection 1mL ampule |
Product containing precisely hydroxocobalamin (as hydroxocobalamin acetate) 1 milligram/1 milliliter conventional release solution for injection (clinical drug) |
Hydroxocobalamin 2.5g powder for conventional release solution for injection vial |
Product containing only hydroxocobalamin in parenteral dose form (medicinal product form) |
Hydroxocobalamin 2.5g powder for injection solution vial + diluent |
Product containing only hydroxocobalamin in parenteral dose form (medicinal product form) |
Hydroxyethylcellulose 0.44% conventional release eye drops |
Product containing only hyetellose (medicinal product) |
Hydroxyethylcellulose 0.44% single-use eye drops |
Product containing only hyetellose (medicinal product) |
Hydroxypropyl methylcellulose 0.32% conventional release eye drops |
Hypromellose 3.2 mg/mL eye solution |
Hydroxypropyl methylcellulose 0.32% single-use eye drops |
Hypromellose 3.2 mg/mL eye solution |
Hydroxypropylmethylcellulose 2% eye drops |
Product containing precisely hypromellose 2 milligram/1 milliliter conventional release eye solution (clinical drug) |
Hymenoptera species |
Order Hymenoptera (organism) |
Hyoscine butylbromide allergy |
Allergy to hyoscine |
Hyoscine hydrobromide 0.125% eye drops |
Hyoscine (as hyoscine hydrobromide) 1.25 mg/mL eye solution |
Hyoscine hydrobromide 0.25% eye drops |
Product containing precisely scopolamine (as scopolamine hydrobromide) 2.5 milligram/1 milliliter conventional release eye solution (clinical drug) |
Hyoscine hydrobromide 0.5% eye drops |
Hyoscine (as hyoscine hydrobromide) 5 mg/mL eye solution |
Hyoscine hydrobromide allergy |
Allergy to hyoscine |
Hyoscyamine sulfate 0.031mg/1 mL |
Hyoscyamine only product |
Hyoscyamine sulfate 0.125mg/5mL elixir |
Hyoscyamine sulfate 25 microgram/mL oral solution |
Hyoscyamine sulfate 0.125mg/5mL liquid |
Hyoscyamine sulfate 25 microgram/mL oral solution |
Hyoscyamine sulfate 0.125mg/mL liquid |
Hyoscyamine sulfate 25 microgram/mL oral solution |
Hyperalphaglobulinemia |
Hyperalphaglobulinaemia |
Hyperbetaglobulinemia |
Hyperbetaglobulinemia |
Hypercalcemia caused by thiazide AND vitamin A |
Hypercalcemia caused by thiazide and/or retinol (disorder) |
Hyperchromia |
Hyperchromatism |
Hypercupremia |
Blood copper level above reference range |
Hypercupremia |
Blood copper level above reference range |
Hyperglobulinemia |
Hyperglobulinaemia |
Hyperglycemia clinical management plan |
Hyperglycemia clinical management plan |
Hyperglycemia self management plan |
Hyperglycemia self management plan |
Hyperhidrosis, premature cavities and premolar aplasia |
A rare autosomal dominant ectodermal dysplasia syndrome characterized by premolar aplasia, hyperhidrosis, and premature graying of the hair. Additional features may include a narrow palate, hypoplastic nails, eyebrow anomalies, a unilateral simian crease, and poorly formed dermatoglyphics. |
Hyperinsulinemia due to benign insulinoma |
Hyperinsulinemia due to malignant insulinoma |
Hyperinsulinemia due to insulinoma |
Hyperinsulinemia due to malignant insulinoma |
Hyperlipidaemia NOS |
Hyperlipidemia |
Hyperlipidemia NOS |
Hyperlipidemia |
Hyperlipidemia clinical management plan |
Hyperlipidaemia clinical management plan |
Hypermenorrhea |
Menorrhagia (finding) |
Hypermobility |
Musculoskeletal hypermobility |
Hyperpyrexia |
Hyperpyrexia (finding) |
Hypersensitivity alveolitis in lungworm infection |
Hypersensitivity pneumonitis |
Hypersensitivity skin test NOS |
Hypersensitivity skin testing |
Hypersensitivity skin test NOS |
Hypersensitivity skin testing |
Hypersomnolence caused by substance |
Drug-induced hypersomnia |
Hypertension clinical management plan |
Hypertension clinical management plan (record artifact) |
Hypertension of pregnancy NOS |
Pregnancy-induced hypertension |
Hypertension of pregnancy NOS |
Pregnancy-induced hypertension |
Hypertensive disease NOS |
Hypertensive disorder, systemic arterial (disorder) |
Hypertensive disease NOS |
Hypertensive disorder, systemic arterial (disorder) |
Hypertensive ischemic ulcer |
Ischemic ulcer of skin due to arterial hypertension (disorder) |
Hyperthermia in newborn, unspecified |
Hyperthermia in newborn |
Hypertonic saline |
Sodium chloride only product |
Hypertonic uterine inertia with antenatal problem |
Hypertonic uterine inertia |
Hypertrichosis and acromegaloid facial appearance syndrome |
Cantu's syndrome |
Hypertrichosis universalis |
Congenital hypertrichosis |
Hypertrophic cardiomyopathy associated with another disorder |
Hypertrophic cardiomyopathy due to disorder |
Hypertrophic cardiomyopathy secondary to Friedreich's ataxia |
Hypertrophic cardiomyopathy due to Friedreich ataxia |
Hypertrophic cardiomyopathy secondary to hyperthyroidism |
Hypertrophic cardiomyopathy due to hyperthyroidism |
Hypertrophic cardiomyopathy secondary to neuromuscular disorder |
Hypertrophic cardiomyopathy due to neuromuscular disorder |
Hypertrophy of bone |
External hyperostosis |
Hypertrophy of bone and cartilage |
External hyperostosis |
Hypertrophy of cartilage |
Hypertrophy |
Hypnotic |
Hypnotic agent (substance) |
Hypnotic agent |
Hypnotic agent (substance) |
Hypnotic dependence with current use |
Hypnotic dependence (disorder) |
Hypnotic withdrawal syndrome without complication |
Hypnotic withdrawal |
Hypoactive sexual desire disorder |
Lack or loss of sexual desire |
Hypoalphaglobulinemia |
Hypoalphaglobulinaemia |
Hypobetaglobulinemia |
Hypoalphaglobulinaemia |
Hypoglobulinemia |
Hypoglobulinaemia |
Hypoglycaemia unspecified |
Hypoglycaemia |
Hypoglycemia clinical management plan |
Hypoglycemia clinical management plan (record artifact) |
Hypoglycemia self management plan |
Hypoglycaemia self management plan |
Hypoglycemia unspecified |
Hypoglycaemia |
Hypoglycemia unspecified NOS |
Hypoglycaemia |
Hypogonadism, diabetes mellitus, alopecia, mental retardation and electrocardiographic abnormalities |
Woodhouse-Sakati syndrome is a multisystemic disorder characterized by hypogonadism, alopecia, diabetes mellitus, intellectual deficit and extrapyramidal signs with choreoathetoid movements and dystonia. |
Hypopharyngeal TNM finding |
American Joint Committee on Cancer allowable value |
Hypophysectomy by other specified approach |
Hypophysectomy |